[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346601-105":59,"doc-detail-346601-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","insights-from-genomic-sequencing-of-preclinical-breast-cancer-models-establish-human-parallels-to-increase-therapeutic-applicability","Insights from Genomic Sequencing of Preclinical Breast Cancer Models - Establish Human Parallels to Increase Therapeutic Applicability","","Breast cancer’s inherent heterogeneity complicates mechanism discovery and therapy selection, motivating diverse preclinical models. Review synthesizes how carcinogen-induced, genetically engineered mouse models, and patient-derived xenografts can be aligned to humans through sequencing. Using TCGA and COSMIC as key references, the article emphasizes conserved whole-genome and gene-expression events across species. Identified subtype-relevant drivers enable conserved therapeutic target discovery and support selecting appropriate mouse models to strengthen translational applicability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/insights-from-genomic-sequencing-of-preclinical-breast-cancer-models-establish-human-parallels-to-increase-therapeutic-applicability/346601/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/insights-from-genomic-sequencing-of-preclinical-breast-cancer-models-establish-human-parallels-to-increase-therapeutic-applicability/346601.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is breast cancer modeling considered challenging?","Question",{"text":112,"@type":113},"Breast cancer’s heterogeneity complicates mechanism discovery and therapy translation. The review stresses aligning mouse model relevance to human biology through sequencing-based comparison.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which projects are highlighted as pivotal for understanding human cancer driving events?",{"text":117,"@type":113},"TCGA and COSMIC are described as pivotal for identifying driving events, including mutation patterns and secondary events beyond primary oncogenic activation or suppressor loss.",{"name":119,"@type":110,"acceptedAnswer":120},"What sequencing approach revealed conserved events between human and mouse model systems?",{"text":121,"@type":113},"The combination of WGS and gene expression analysis identifies conserved critical events that drive breast cancer across species.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346601,1790958462,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Journal of Mammary Gland Biology and Neoplasia (2026) 31:7  \n[https://doi.org/10.1007/s1091](https://doi.org/10.1007/s1091) 1-026-09599-7  \nREVIEW  \nInsights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability  \nAnthony J. Schulte1 · Eran R. Andrechek2  \nReceived: 18 November 2025 / Accepted: 22 January 2026 © The Author(s) 2026  \nAbstract  \nThe study of breast cancer is complicated by the heterogeneity inherent within the disease. Numerous models have been developed to study the initiation, progression, and treatment of breast cancer. These include carcinogen induced mouse models, genetically engineered mouse models, and patient derived xenografts. The relevance of these mouse models to humans must be precisely defined for appropriate understanding of disease mechanisms to derive intervening treatments. Sequencing projects such as The Cancer Genome Atlas Project (TCGA) and Catalogue Of Somatic Mutations In Cancer (COSMIC) were pivotal developments in understanding driving events in human cancers. These studies have revealed that in addition to activation of strong oncogenes, or loss of tumor suppressors, that secondary events are necessary for tumor development and progression. These techniques should also be applied to mouse models of human breast cancer. For all the available models studied and reviewed here, whole genome sequencing (WGS) in conjunction with gene expression analysis has revealed conserved events between human and mouse model systems. This identification of conserved, critical events driving breast cancer has led to novel targets based on breast cancer subtype, ultimately resulting in new therapeutic opportunities. The combination of sequencing and choice of the appropriate mouse model can provide a powerful tool in developing appropriate pre-clinical models of breast cancer.  \nKeywords Breast cancer · Mouse models · Sequencing · Therapeutic targeting  \nIntroduction Background  \nBreast cancer is classified through a number of systems, ranging from TMN (tumor size, metastasis present, nodes positive) to ER (estrogen receptor), PR (progesterone receptor), and HER2 (Human Epidermal growth factor Receptor 2) status. More recently, breast cancer has been classified by gene expression. Each of these classification systems has revealed substantial heterogeneity across breast cancer  \n􀀍 Eran R. Andrechek [Andrech1@msu.edu](Andrech1@msu.edu)  \n1 Department of Pharmacology and Toxicology, Michigan State University, 1355 Bogue St, East Lansing, MI 48824, USA  \n2 Department of Physiology, Michigan State University, 2194 BPS Building, 567 Wilson Road, East Lansing, MI 48824, USA  \npatients. With the advent of gene expression profiling of breast cancer, the subsets of genes responsible for variation in growth rate, signaling pathways, and cellular composition became more clear [1, 2] . Ultimately, this resulted in the Pam50 classifier, placing tumors into Luminal A, Luminal B, HER2-enriched, and basal-like subtypes [3] . Further gene expression studies expanded subtype classifications to include claudin-low [4] . The identification of subtypes that harbor unique gene patterns underscored the need to understand the complex gene interactions that impact clinical outcome. In 2012, The Cancer Genome Atlas (TCGA) published the initial findings of integrated genomic information, reinforcing the idea that breast cancer converges into phenotypic classes consistent with the observed genomic and epigenetic alterations. Overall, TCGA observed high incidence (> 10%) of mutations in TP53, PIK3CA, and GATA3 in breast cancer with subtypes enriched in unique patterns. For example, enrichment of GATA3, PIK3CA, and MAP3K1 was noted in Luminal A tumors. TP53 mutations were frequent in basal-like tumors and as expected, HER2 amplification was enriched in the HER2 +subtype [5] . However,  \n1 3  \nthere are a variety of additional genetic and epigenetic alterations that are","cbCaijE76YMcDROx","https://ap.wps.com/l/cbCaijE76YMcDROx","pdf",1298609,12,"English","# Abstract\n# Introduction\n## Breast cancer classification and gene expression subtypes\n# Models of Breast Cancer\n## In vitro models\n## Mouse models","[{\"question\":\"Why is breast cancer modeling considered challenging?\",\"answer\":\"Breast cancer’s heterogeneity complicates mechanism discovery and therapy translation. The review stresses aligning mouse model relevance to human biology through sequencing-based comparison.\"},{\"question\":\"Which projects are highlighted as pivotal for understanding human cancer driving events?\",\"answer\":\"TCGA and COSMIC are described as pivotal for identifying driving events, including mutation patterns and secondary events beyond primary oncogenic activation or suppressor loss.\"},{\"question\":\"What sequencing approach revealed conserved events between human and mouse model systems?\",\"answer\":\"The combination of WGS and gene expression analysis identifies conserved critical events that drive breast cancer across species.\"}]","Insights from Genomic Sequencing of Preclinical Breast Cancer Models - Establish Human Parallels to Increase Therapeutic Applicability | PDF",1790062100,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78285b5512178bf38e8a997b5fa0ca2c.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5c589c9a30555ff28b7fe4a90fe0132.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9c2223fb497841c10f1bf5b007ed088.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19c702fecb2402114b47be078cec0dde.webp",980,1301]